Gsk (GSK) Net Income Attributable to Noncontrolling Interests (2009 - 2026)

Over the trailing twelve months to Sep 30, 2026, Gsk reported Net Income Attributable to Noncontrolling Interests of $3.35 billion, down 3.3% year-over-year; for the year ended Dec 31, 2025, it was $755.51 million, up 57.2% from the prior year.

• Net Income Attributable to Noncontrolling Interests carries a five-year compound annual growth rate of -1.6% (years ended Dec 2020 to Dec 2025).
• Going back by year, Net Income Attributable to Noncontrolling Interests was $480.63 million in the year ended Dec 31, 2024 (+1.7%), $472.65 million in the year ended Dec 31, 2023 (-42.6%), $823.01 million in the year ended Dec 31, 2022 (-15.9%) and $978.25 million in the year ended Dec 31, 2021 (+19.2%).
• The five-year range for quarterly Net Income Attributable to Noncontrolling Interests is $23.57 million (the quarter ended Sep 30, 2022) to $2.89 billion (the quarter ended Sep 30, 2025).
• Year-over-year, Net Income Attributable to Noncontrolling Interests has declined for three consecutive quarters, with growth averaging 137.9% over the last seven quarters.
• The fastest year-over-year change in Net Income Attributable to Noncontrolling Interests over five years came in the quarter ended Dec 31, 2025 (growth of 582.6%), and the weakest in the quarter ended Dec 31, 2023 (a decline of 89.0%).
• Business Quant data shows GSK's Net Income Attributable to Noncontrolling Interests at $158.32 million (quarter ended Jun 30, 2026), $137.51 million (quarter ended Mar 31, 2026) and $762.19 million (quarter ended Dec 31, 2025) in the three quarters before the quarter ended Sep 30, 2026.